Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials

The Lancet

Volumn 389, Issue 10085, 2017, Pages 2226-2237

  Böhm, Michael ^a   Schumacher, Helmut ^b   Teo, Koon K ^c   Lonn, Eva M ^c   Mahfoud, Felix ^a   Mann, Johannes F E ^d   Mancia, Giuseppe ^e   Redon, Josep ^f   Schmieder, Roland E ^d   Sliwa, Karen ^g   Weber, Michael A ^h   Williams, Bryan ⁱ   Yusuf, Salim ^c  

^a SAARLAND UNIVERSITY   (Germany)

^b Ingelheim ^*  (Germany)

^c MCMASTER UNIVERSITY   (Canada)

^d UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^e UNIVERSITY OF MILANO BICOCCA   (Italy)

^f UNIVERSITY OF VALENCIA   (Spain)

^g UNIVERSITY OF CAPE TOWN   (South Africa)

^h SUNY Downstate Medical Center   (United States)

ⁱ University College London ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RAMIPRIL; TELMISARTAN; ANTIHYPERTENSIVE AGENT; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; COMPARATIVE STUDY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; HEART FAILURE; HEART INFARCTION; HIGH RISK PATIENT; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; BLOOD PRESSURE; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; COMPLICATION; DRUG EFFECT; FOLLOW UP; HOSPITALIZATION; HYPERTENSION; HYPOTENSION; META ANALYSIS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY (TOPIC); PATHOPHYSIOLOGY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICS AND NUMERICAL DATA;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BENZOATES; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; HYPERTENSION; HYPOTENSION; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; RAMIPRIL; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85017124138     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(17)30754-7     Document Type: Article

References (35)

1. Mancia, G, Fagard, R, Narkiewicz, K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 34 (2013), 2159–2219.
2. Rydén, L, Grant, PJ, Anker, SD, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 34 (2013), 3035–3087.
3. James, PA, Oparil, S, Carter, BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 311 (2014), 507–520.
4. Psaty, BM, Lumley, T, Furberg, CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 289 (2003), 2534–2544.
5. Law, MR, Morris, JK, Wald, NJ, Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ, 338, 2009, b1665.
6. Mancia, G, Grassi, G, Aggressive blood pressure lowering is dangerous: the J-curve: pro side of the arguement. Hypertension 63 (2014), 29–36.
7. Cooper-DeHoff, RM, Gong, Y, Handberg, EM, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA 304 (2010), 61–68.
8. Messerli, FH, Mancia, G, Conti, CR, et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous?. Ann Intern Med 144 (2006), 884–893.
9. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 358 (2001), 1033–1041.
10. Vidal-Petiot, E, Ford, I, Greenlaw, N, et al. Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study. Lancet 388 (2016), 2142–2152.
11. Ambrosius, WT, Sink, KM, Foy, CG, et al. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT). Clin Trials 11 (2014), 532–546.
12. Cushman, WC, Evans, GW, Byington, RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 362 (2010), 1575–1585.
13. Benavente, OR, Coffey, CS, Conwit, R, et al. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet 382 (2013), 507–515.
14. Wright, JT Jr, Williamson, JD, Whelton, PK, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 373 (2015), 2103–2116.
15. Yusuf, S, Teo, KK, Pogue, J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358 (2008), 1547–1559.
16. Yusuf, S, Teo, K, Anderson, C, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 372 (2008), 1174–1183.
17. Durrleman, S, Simon, R, Flexible regression models with cubic splines. Stat Med 8 (1989), 551–561.
18. Vuong, QH, Likelihood ratio tests for model selection and non-nested hypotheses. Econometrica 57 (1989), 307–333.
19. Sleight, P, Redon, J, Verdecchia, P, et al. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens 27 (2009), 1360–1369.
20. Redon, J, Mancia, G, Sleight, P, et al. Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial). J Am Coll Cardiol 59 (2012), 74–83.
21. Dorresteijn, JA, van der Graaf, Y, Spiering, W, et al. Relation between blood pressure and vascular events and mortality in patients with manifest vascular disease: J-curve revisited. Hypertension 59 (2012), 14–21.
22. Verdecchia, P, Reboldi, G, Angeli, F, et al. Systolic and diastolic blood pressure changes in relation with myocardial infarction and stroke in patients with coronary artery disease. Hypertension 65 (2015), 108–114.
23. Sim, JJ, Shi, J, Kovesdy, CP, Kalantar-Zadeh, K, Jacobsen, SJ, Impact of achieved blood pressures on mortality risk and end-stage renal disease among a large, diverse hypertension population. J Am Coll Cardiol 64 (2014), 588–97.21.
24. Weber, MA, Bakris, GL, Hester, A, et al. Systolic blood pressure and cardiovascular outcomes during treatment of hypertension. Am J Med 126 (2013), 501–508.
25. Mancia, G, Kjeldsen, SE, Zappe, DH, et al. Cardiovascular outcomes at different on-treatment blood pressures in the hypertensive patients of the VALUE trial. Eur Heart J 37 (2016), 955–964.
26. Brunström, M, Carlberg, B, Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. BMJ, 352, 2016, i717.
27. Xie, X, Atkins, E, Lv, J, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet 387 (2016), 435–443.
28. Sundström, J, Arima, H, Woodward, M, et al. Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. Lancet 384 (2014), 591–598.
29. Lonn, EM, Bosch, J, López-Jaramillo, P, et al. Blood-pressure lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med 374 (2016), 2009–2020.
30. Mancia, G, Grassi, G, Systolic and diastolic blood pressure control in antihypertensive drug trials. J Hypertens 20 (2002), 1461–1464.
31. Nwankwo, T, Yoon, SS, Burt, V, Gu, Q, Hypertension among adults in the United States: National Health and Nutrition Examination Survey, 2011–2012. NCHS Data Brief 133 (2013), 1–8.
32. Kjeldsen, SE, Lund-Johansen, P, Nilsson, PM, Mancia, G, Unattended blood pressure measurements in the systolic blood pressure intervention trial: implications for entry and achieved blood pressure values compared with other trials. Hypertens 67 (2016), 808–812.
33. Zanchetti, A, Liu, L, Mancia, G, et al. Continuation of the ESH-CHL-SHOT trial after publication of the SPRINT: rationale for further study on blood pressure targets of antihypertensive treatment after stroke. J Hypertens 34 (2016), 393–396.
34. Zanchetti, A, Blood pressure targets of antihypertensive treatment: up and down the J-shaped curve. Eur Heart J 31 (2010), 2837–2840.
35. Anderson, AH, Yang, W, Townsend, RR, et al. Time-updated systolic blood pressure and the progression of chronic kidney disease: a cohort study. Ann Intern Med 162 (2015), 258–265.